Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium Patent Expiration
Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium was first introduced by Gilead Sciences Inc
Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium Patents
Given below is the list of patents protecting Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Bixlenvo Sunlenca Starter Pack (copackaged) | US11267799 | Solid forms of an HIV capsid inhibitor | Aug 16, 2038 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US10071985 | Therapeutic compounds | Aug 17, 2037 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US10654827 | Therapeutic compounds | Aug 17, 2037 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US10385067 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepin-8-olate | Jun 19, 2035 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US9708342 | Sodium (2R,5S,13aR)-7,9-dioxo-10-((2,4,6-trifluorobenzyl)carbamoyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1′,2′:4,5]pyrazino[2, 1-b][1, 3]oxazepin-8-olate | Jun 19, 2035 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US9951043 | Therapeutic compounds | Feb 28, 2034 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US9216996 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections | Dec 19, 2033 | Gilead Sciences Inc |
| Bixlenvo Sunlenca Starter Pack (copackaged) | US9732092 | Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]OXAZEPINES and methods for treating viral infections | Dec 19, 2033 | Gilead Sciences Inc |
Bictegravir Sodium, Lenacapavir Sodium; Lenacapavir Sodium's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List